Journal article
Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant plasmodium falciparum: Clinical outcomes from the queerpam study
SM Taylor, AL Antonia, E Chaluluka, V Mwapasa, G Feng, ME Molyneux, FO Ter Kuile, SR Meshnick, SJ Rogerson
Clinical Infectious Diseases | Published : 2012
DOI: 10.1093/cid/cis301
Abstract
Background. Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of efforts in sub-Saharan Africa to prevent pregnancy-associated malaria (PAM). Recent studies report that drug resistance may cause IPTp-SP to exacerbate PAM morbidity, raising fears that current policies will cause harm as resistance spreads.Methods.We conducted a serial, cross-sectional analysis of the relationships between IPTp-SP receipt, SP-resistant Plasmodium falciparum, and PAM morbidity in delivering women during a period of 9 years at a single site in Malawi. PAM morbidity was assessed by parasite densities, placental histology, and birth outcomes.Results.The p..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by the Malaria in Pregnancy Consortium, which is funded through a grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine (to F. O. tK.). Sample collection was funded by a Career Development Fellowship and a Senior Overseas Biomedical Research Fellowship awarded by the Wellcome Trust (to S. J. R.) and by grants from the National Institutes of Health (NIH; AI 49084), NIH-Fogarty International Center (5 D43 TW00908), and the Center for AIDS Research at the University of North Carolina (to S. R. M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.